Pulmonx LUNG 深 滬

Pulmonx to Participate in Upcoming Investor Conferences

Pulmonx Corporation, a global leader in minimally invasive treatments for severe lung disease, announced its participation in two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 9 in Boston and the Lake Street Best Ideas Growth (BIG10) Conference on September 10 in New York. Pulmonx specializes in treating chronic obstructive pulmonary disease (COPD) with products like the Zephyr® Endobronchial Valve, which has r...

08-27 20:05

Pulmonx shares are trading lower after the company announced an offering.

Pulmonx shares are trading lower after the company announced an offering.

07-30 04:48

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Pulmonx Corporation will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The company, a global leader in minimally invasive treatments for severe lung disease, will discuss its innovative solutions for COPD and emphysema, including the Zephyr® Endobronchial Valve. A live and archived webcast of the event will be available on Pulmonx's investor website.

07-28 20:05

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulmonx Corporation granted 84,300 restricted stock units (RSUs) to 17 new employees hired in the first two quarters of 2026, vesting over four years. The equity awards were approved under the 2025 Inducement Plan to incentivize new hires, in compliance with Nasdaq Listing Rule 5635(c)(4). Pulmonx is a global leader in minimally invasive lung disease treatments, with FDA-approved products like the Zephyr® Endobronchial Valve for severe emphysema/...

06-01 20:05

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

04-28 20:05

Earnings Summary: Pulmonx Q4

The Q4 earnings report for Pulmonx (NASDAQ:LUNG) was released on Wednesday, Mar...

03-05 05:10

Pulmonx Sees FY2026 Sales $90.000M-$92.000M vs $94.227M Est

Pulmonx (NASDAQ:LUNG) sees FY2026 sales of $90.000 million-$92.000 million vs $94.227 million analyst estimate.

03-05 05:09

Pulmonx Q4 EPS $(0.25) Beats $(0.39) Estimate, Sales $22.598M Beat $21.728M Estimate

Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.39) by 36.22 percent. This is a 24.24 percent increase over losses of $(0.33) per share from the same

03-05 05:08

Pulmonx Announces Closing of up to $60 Million Credit Facility

Pulmonx Corporation announced the closing of a $60 million five-year credit facility with Perceptive Advisors to refinance its existing debt and provide additional capital through 2027. The facility includes an initial $40 million term loan and an option to draw an additional $20 million, subject to revenue milestones. The new facility, which is interest-only until 2031, features favorable terms that strengthen the company’s capital structure. Pu...

03-04 21:05

Earnings Scheduled For March 4, 2026

Companies Reporting Before The Bell • Dingdong (Cayman) (NYSE:DDL) is estimated...

03-04 19:11